SCHEMBL4069351

SCHEMBL4069351

C#Cc1cnnc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.44
TGFBR1 P36897 1/20 0.37
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 5/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 1/20 0.32
GRM5 P41594 1/20 0.32
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MAOA P21397 3/20 0.32
TP53 P04637 2/20 0.32
CYP3A4 P08684 2/20 0.32
GOT1 P17174 2/20 0.32
MPO P05164 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
CYP2D6 P10635 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013659 0.80 GPR3 (0.44) GPR3TGFBR1MAPTHTTKDM4E
SCHEMBL2009242 0.80 GPR3 (0.44) GPR3TGFBR1MAPTLMNAHTT
SCHEMBL22124911 0.77 GPR3 (0.41) GPR3TGFBR1LMNAHTTKDM4E
SCHEMBL13765861 0.74 GPR3 (0.39) GPR3TGFBR1MAPTLMNAHTT
SCHEMBL736202 0.69 NCF1 (0.50) GPR3MAPTLMNAHTTKDM4E
SCHEMBL30098629 0.69 NCF1 (0.50) GPR3MAPTLMNAHTTKDM4E
SCHEMBL436407 0.68 GPR3 (0.50) GPR3TGFBR1MAPTKDM4ECYP1A2
SCHEMBL276531 0.68 GPR3 (0.50) GPR3TGFBR1MAPTLMNAHTT
SCHEMBL21532813 0.68 GPR3 (0.50) GPR3TGFBR1MAPTLMNAHTT
SCHEMBL3883304 0.68 GPR3 (0.50) GPR3TGFBR1MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090561-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-9090561-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-9090561-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-8461167-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-06-11 US disclosed
US-8461167-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-06-11 US disclosed
US-8461167-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-06-11 US disclosed
US-20130018046-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-01-17 US disclosed
US-20130018046-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-01-17 US disclosed
US-20090176781-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. 2009-07-09 US disclosed
US-20090176781-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. 2009-07-09 US disclosed
EP-2023933-A2 ACETYLENIC HETEROARYL COMPOUNDS ARIAD PHARMACEUTICALS, INC. (US) 2009-02-18 EP disclosed
WO-2007133560-A9 ACETYLENIC HETEROARYL COMPOUNDS ARIAD PHARMA INC (US) 2008-11-13 WO disclosed
WO-2007133560-A2 ACETYLENIC HETEROARYL COMPOUNDS ARIAD PHARMACEUTICALS, INC. (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176781-A1 Acetylenic Heteroaryl Compounds NAT1, AADAC, ACACA GPR3 3431/4885TGFBR1 3199/4885MAPT 1839/4885
US-20130018046-A1 Acetylenic Heteroaryl Compounds NAT1, AADAC, ACACA GPR3 3431/4885TGFBR1 3199/4885MAPT 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.